SEMAGLUTIDE

Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) used in research to explore incretin biology, energy homeostasis, and glucose regulation. Engineered for structural stability against dipeptidyl peptidase-4 degradation, semaglutide demonstrates extended half-life and enhanced receptor affinity, allowing investigation of chronic metabolic signaling, appetite modulation, and pancreatic β-cell responsiveness in experimental models.

Target: Glucagon-like peptide-1 receptor (GLP-1R), a class-B G-protein–coupled receptor expressed in pancreatic islets, CNS, and gastrointestinal tissues.
Mode: Ligand binding activates the cAMP/PKA pathway → glucose-dependent insulin secretion ↑, glucagon secretion ↓, gastric emptying slowed, and hypothalamic satiety circuits modulated.
Design: Modified at position-8 with a fatty-acid side chain enabling albumin binding → prolonged plasma half-life (~160 h) and sustained receptor engagement in preclinical and translational settings.

Incretin pharmacodynamics and receptor kinetics • β-cell insulinotropic response profiling • Appetite and reward-pathway mapping • Glucose and lipid metabolism studies • Comparative modeling of GLP-1RAs for chronic metabolic regulation and neuroendocrine feedback.

Revitalized Health peptides are synthesized under cGMP-aligned laboratory conditions using pharmaceutical-grade inputs. Each semaglutide batch is confirmed at ≥99 % purity via HPLC and structure verified by LC-MS/MS. Each lot undergoes solubility, pH, and microbial/endotoxin testing per research-grade specifications. Full Certificates of Analysis are available for verification of identity and purity.

Store lyophilized material at 2–8 °C in a dry, light-protected environment. After reconstitution with bacteriostatic water, maintain at 2–8 °C and use within 20 days. Avoid multiple freeze–thaw cycles to preserve tertiary structure and receptor-binding fidelity.

For laboratory research use only. Not intended for human consumption, therapeutic, or diagnostic application. Distributed solely to qualified professionals conducting controlled scientific studies.

Identity: Semaglutide, acylated GLP-1 receptor agonist engineered for albumin binding and DPP-4 resistance (allowing once-weekly SC dosing; oral forms use absorption enhancers).
Mode: Activates GLP-1R on pancreatic β-cells and CNS/GI targets → ↑ glucose-dependent insulin, ↓ glucagon, slowed gastric emptying, and reduced appetite/energy intake; downstream effects include improved glycemia and weight metrics in trials.
Analytics: Identity/purity by HPLC/LC-MS; peptide content & counter-ion; stability (accelerated/real-time). PD readouts: fasting/post-prandial glucose, HbA1c, body weight & composition, OGTT, gastric emptying tests, indirect calorimetry where applicable. Monitoring (class): GI tolerability (nausea/vomiting/diarrhea), gallbladder events, heart-rate change; pancreatitis symptoms; thyroid C-cell signal from rodent data context. Avoid disease-treatment claims on marketing pages.